



Saint Alphonus Physician Surpasses Procedure Milestone Using Stereotaxis Niobe® ES System

June 14, 2016

ST. LOUIS, June 14, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Saint Alphonus Health System in Idaho today announced that Dr. Margot Vloka has completed more than 500 cardiac ablation procedures using the Niobe® ES remote magnetic navigation system. Dr. Vloka is a board-certified clinical cardiac electrophysiologist (EP) at the Saint Alphonus Stereotaxis lab and a Fellow of the Heart Rhythm Society.

The *Niobe* ES system was introduced in the U.S. at the end of 2011 and installed the following year at Saint Alphonus Health System, making it the first provider in Idaho to utilize remote magnetic navigation for ablation procedures. Having experience with the *Niobe* system while at the Wisconsin Heart Hospital, Dr. Vloka was a vocal proponent of the technology when arriving at Saint Alphonus in late 2014. After training on the latest generation *Niobe* ES system with the aid of the Company's best practices program, Dr. Vloka quickly adopted the *Niobe* ES system as part of her daily clinical routine for the treatment of atrial arrhythmias, ventricular tachycardia, congenital heart disease and other complex cardiac conditions.

"I have always been a 'belt and suspenders' type physician, especially given the delicacy of the cardiovascular system, and with the *Niobe* system, I have complete peace of mind that I am providing the safest approach to cardiac ablation," said Dr. Vloka. "The *Niobe* system's remote, computer-assisted features reduce risk of complications and enable me to create more effective lesions with shorter procedure times than traditional manual and mechanical therapies. As a result, I am able to complete multiple complex procedures each day and, most importantly, my patients are able to resume normal activities with freedom from debilitating arrhythmias."

Tom Reinhardt, Assistant Vice President for Saint Alphonus Health System, said "We are very pleased to be the only healthcare provider in the state to offer this groundbreaking treatment for cardiac ablations. The level of expertise Dr. Vloka has achieved with Stereotaxis technologies continues to raise the bar for EP professionals in the region. The *Niobe* system and its suite of automations has been a strong addition to the Saint Alphonus cardiology services line, expanding our capabilities to better serve patients across the region."

About Saint Alphonus Health System

As a faith-based Catholic ministry and not-for-profit health system, Saint Alphonus Health System reinvests in the communities we serve, through charity care and other benefits. Our goal is to improve the health and well-being of people by emphasizing care that is patient-centered, physician-led, innovative and community-based. Saint Alphonus Health System serves the people of southwestern Idaho, eastern Oregon and northern Nevada through these facilities: Saint Alphonus Regional Medical Center - Boise, ID; Saint Alphonus Medical Center - Nampa, ID; Saint Alphonus Medical Center - Ontario, OR; Saint Alphonus Medical Center - Baker City, OR; and, Saint Alphonus Medical Group with primary and specialty care providers at over 60 clinic locations, all of which are members of the Saint Alphonus Health Alliance, a network of over 1900 employed and independent providers. Saint Alphonus is a proud affiliate of Trinity Health, one of the largest multi-institutional Catholic health care delivery systems in the nation. Trinity Health serves people and communities in 21 states from coast to coast with 88 hospitals and 126 continuing care facilities, home health and hospice programs, and PACE center locations that provide more than 2.5 million visits annually. To find out more go to: www.saintalphonus.org.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.

The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contact :

Martin C. Stammer
Chief Financial Officer
314-678-6155

Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com



Stereotaxis, Inc.